| dc.description.abstract | Background: Polycystic Ovary Syndrome (PCOS) is a metabolic and reproductive disorder
affecting women of reproductive age, characterized by hyperandrogenemia, ovarian
dysfunction (chronic anovulation and infertility), and polycystic ovaries, and is associated
with metabolic consequences, including insulin resistance, type 2 diabetes, and obesity.
HOMA-IR is the gold standard method used to assess insulin resistance.
Methods: This study employed a quasi-experimental pre- and post-test design to analyze
the effect of lipase inhibitor therapy (orlistat) on HOMA-IR in PCOS patients. The study
included 25 subjects, with a 20% dropout rate, resulting in a total of 30 subjects. Blood
samples were collected from the cubital vein, followed by statistical analysis of the data.
Results: The majority of PCOS women were aged >30 years (55,2%) with BMI category in
overweight (34,5%) or obese (37,9%). Of the 29 patients, only 8 patients (27,6%) were
diagnosed as lean PCOS, There was no significant difference in HOMA-IR values between
before and after orlistat administration in subjects aged > 30 years and under < 30 years
(p=0,416 and 0,266), The mean body weight before and after administration was not
statistically significantly different (p = 0,641), Mean HOMA-IR in obese PCOS women
before and after intervention conducted by bivariate analysis showed a significant
difference in HOMA-IR levels based on BMI before intervention (p=0,049) and after
intervention (p=0,01) orlistat therapy
Conclusion: Administration of lipase inhibitors to PCOS patients has the effect of reducing
HOMA-IR values in obese subjects, but has less effect on overweight and normoweight
subjects (lean PCOS). | en_US |
